Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Bayer takes Alport syndrome drug into phase 2

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome.

Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Dec 4, 2025-

Bayer begins phase 2 trial of new Alport syndrome therapy

New study to test Sema3A antibody in rare genetic kidney disease